AU2017315783C1 - Use of pridopidine for treating a subject with early stage huntington disease - Google Patents

Use of pridopidine for treating a subject with early stage huntington disease Download PDF

Info

Publication number
AU2017315783C1
AU2017315783C1 AU2017315783A AU2017315783A AU2017315783C1 AU 2017315783 C1 AU2017315783 C1 AU 2017315783C1 AU 2017315783 A AU2017315783 A AU 2017315783A AU 2017315783 A AU2017315783 A AU 2017315783A AU 2017315783 C1 AU2017315783 C1 AU 2017315783C1
Authority
AU
Australia
Prior art keywords
human patient
bid
pridopidine
patient
early stage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017315783A
Other languages
English (en)
Other versions
AU2017315783B2 (en
AU2017315783A1 (en
Inventor
Beth Borowsky
Eli Eyal
Igor D. GRACHEV
Michael Hayden
Spyridon Papapetropoulos
Juha-Matti Savola
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prilenia Neurotherapeutics Ltd
Original Assignee
Prilenia Neurotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Neurotherapeutics Ltd filed Critical Prilenia Neurotherapeutics Ltd
Publication of AU2017315783A1 publication Critical patent/AU2017315783A1/en
Assigned to Prilenia Neurotherapeutics Ltd reassignment Prilenia Neurotherapeutics Ltd Amend patent request/document other than specification (104) Assignors: PRILENIA THERAPEUTICS DEVELOPMENT LTD.
Publication of AU2017315783B2 publication Critical patent/AU2017315783B2/en
Priority to AU2020223736A priority Critical patent/AU2020223736B2/en
Application granted granted Critical
Publication of AU2017315783C1 publication Critical patent/AU2017315783C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017315783A 2016-08-24 2017-08-24 Use of pridopidine for treating a subject with early stage huntington disease Active AU2017315783C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020223736A AU2020223736B2 (en) 2016-08-24 2020-08-27 Use of pridopidine for treating a subject with early stage huntington disease

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662379175P 2016-08-24 2016-08-24
US62/379,175 2016-08-24
US201662395263P 2016-09-15 2016-09-15
US62/395,263 2016-09-15
US201662411511P 2016-10-21 2016-10-21
US62/411,511 2016-10-21
US201662416685P 2016-11-02 2016-11-02
US62/416,685 2016-11-02
PCT/US2017/048461 WO2018039477A1 (en) 2016-08-24 2017-08-24 Use of pridopidine for treating functional decline

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020223736A Division AU2020223736B2 (en) 2016-08-24 2020-08-27 Use of pridopidine for treating a subject with early stage huntington disease

Publications (3)

Publication Number Publication Date
AU2017315783A1 AU2017315783A1 (en) 2019-04-11
AU2017315783B2 AU2017315783B2 (en) 2020-05-28
AU2017315783C1 true AU2017315783C1 (en) 2020-12-24

Family

ID=61241181

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017315783A Active AU2017315783C1 (en) 2016-08-24 2017-08-24 Use of pridopidine for treating a subject with early stage huntington disease
AU2020223736A Active AU2020223736B2 (en) 2016-08-24 2020-08-27 Use of pridopidine for treating a subject with early stage huntington disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020223736A Active AU2020223736B2 (en) 2016-08-24 2020-08-27 Use of pridopidine for treating a subject with early stage huntington disease

Country Status (17)

Country Link
US (1) US11207310B2 (https=)
EP (2) EP3504187B8 (https=)
JP (2) JP6912574B2 (https=)
CN (2) CN109923102B (https=)
AU (2) AU2017315783C1 (https=)
BR (1) BR112019003732A2 (https=)
CA (2) CA3151507C (https=)
CL (2) CL2019000485A1 (https=)
DK (1) DK3504187T3 (https=)
ES (1) ES3025836T3 (https=)
FI (1) FI3504187T3 (https=)
HU (1) HUE071008T2 (https=)
IL (1) IL311081A (https=)
MX (2) MX390627B (https=)
PL (1) PL3504187T3 (https=)
PT (1) PT3504187T (https=)
WO (1) WO2018039477A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG188298A1 (en) 2010-09-03 2013-04-30 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
PE20160195A1 (es) 2013-06-21 2016-05-14 Teva Pharmaceuticals Int Gmbh Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
TW201613859A (en) * 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
EP4282479A3 (en) 2015-02-25 2024-02-21 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
ES3025836T3 (en) 2016-08-24 2025-06-09 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating functional decline
WO2018039475A1 (en) 2016-08-24 2018-03-01 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating dystonias
NZ750416A (en) 2016-09-15 2022-04-29 Boehringer Ingelheim Int Heteroaryl carboxamide compounds as inhibitors of ripk2
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
AU2018329628B2 (en) 2017-09-08 2021-04-22 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
EP3917380B1 (en) * 2019-01-31 2025-03-19 F. Hoffmann-La Roche AG Assessing progression of huntington's disease
EP3920924A4 (en) 2019-02-04 2022-11-16 Prilenia Neurotherapeutics Ltd. LOW-DOSE PRIDOIDIN FOR THE TREATMENT OF PARKINSON'S DISEASE AND OTHER PARKINSONIC-RELATED DISEASES
JP7436524B2 (ja) * 2019-06-12 2024-02-21 プリレニア ニューロセラピューティクス リミテッド ハンチントン病及びその症状を治療するためのプリドピジン及びその類似体を含む組成物
CN115551505B (zh) * 2020-05-04 2026-03-17 普瑞尼亚神经治疗有限公司 使用选择性s1r激动剂治疗病毒性感染、疾病或病症
WO2022219637A1 (en) * 2021-04-14 2022-10-20 Prilenia Neurotherapeutics Ltd. Treatment of prodromal huntington disease
WO2025164698A1 (ja) * 2024-01-31 2025-08-07 株式会社ケイファーマ ハンチントン病治療剤及び治療用組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060287299A1 (en) * 2003-12-02 2006-12-21 Sheldon Leslie J Combination therapy for dementia, depression and apathy
US20100167286A1 (en) * 2008-06-24 2010-07-01 Parkinson's Institute Pluripotent cell lines and methods of use thereof
US20140378508A1 (en) * 2013-06-21 2014-12-25 IVAX International GmbH Use of high dose pridopidine for treating huntington's disease

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702716D0 (sv) 1997-07-15 1997-07-15 Ross Nicholas Waters Substituted phenylazacycloalkanes in the treatment of cognitive disorders
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
GT200500063A (es) 2004-04-01 2005-10-14 Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
CA2584831C (en) 2004-10-13 2013-09-17 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
DOP2006000273A (es) 2005-12-08 2007-10-15 Aventis Pharma Inc Uso de un antagonista de cb1 para tratar efectos secundarios y sintomas negativos de la esquizofrenia
EP1815857A1 (en) 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
US20070286902A1 (en) 2006-06-07 2007-12-13 Abrika Pharmaceuticals Dosage forms comprising a short acting sedative-hypnotic or salt thereof
SI2146961T1 (sl) 2007-04-12 2014-08-29 IVAX International GmbH N-oksidni in/ali di-N-oksidni derivati stabilizatorjev/modulatorjev dopaminskega receptorja, ki izkazujejo izboljšane profile kardiovaskularnih stranskih učinkov
US8384755B2 (en) 2009-08-26 2013-02-26 Intouch Technologies, Inc. Portable remote presence robot
DK2480218T3 (da) 2009-09-24 2020-08-24 Capsugel Belgium Nv Syreresistente kapsler
US20110206782A1 (en) 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
CN103080343A (zh) 2010-07-02 2013-05-01 Skf公司 机械部件和用于表面硬化的方法
SG188298A1 (en) 2010-09-03 2013-04-30 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US8703763B2 (en) 2011-03-02 2014-04-22 Hoffmann-La Roche Inc. Bridged piperidine derivatives
WO2012159079A1 (en) 2011-05-18 2012-11-22 The Parkinson's Institute Assay to determine lrrk2 activity in parkinson's disease
CN103958469B (zh) 2011-09-07 2016-04-20 梯瓦制药国际有限责任公司 一种新的普利多匹定盐酸盐多晶型形态
MX347209B (es) 2011-12-08 2017-04-19 Teva Pharmaceuticals Int Gmbh La sal de bromhidrato de pridopidina.
US9744155B2 (en) * 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
HK1206297A1 (en) 2012-04-04 2016-01-08 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for combination therapy
EP2900226A4 (en) 2012-09-27 2016-03-30 Teva Pharma COMBINATION OF RASAGILIN AND PRIDOPIDIN FOR TREATING NEURODEGENERATIVE DISORDERS, ESPECIALLY HUNTINGTON'S DISEASE
HK1211525A1 (en) 2012-09-27 2016-05-27 Teva Pharmaceutical Industries Ltd. Laquinimod and pridopidine for treating neurodegenerative disorders
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
PE20161220A1 (es) 2014-01-22 2016-11-23 Teva Pharmaceuticals Int Gmbh Formulaciones de pridopidina de liberacion modificada
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
EP3236964A4 (en) 2014-12-22 2018-09-19 Teva Pharmaceuticals International GmbH L-tartrate salt of pridopidine
EP4282479A3 (en) * 2015-02-25 2024-02-21 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
CA2993183A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
WO2017048457A1 (en) 2015-09-18 2017-03-23 Teva Pharmaceuticals Industries Ltd. Combination of laquinimod and pridopidine to treat multiple sclerosis
US11738012B2 (en) 2016-02-24 2023-08-29 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
WO2018039475A1 (en) 2016-08-24 2018-03-01 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating dystonias
ES3025836T3 (en) 2016-08-24 2025-06-09 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating functional decline
AU2017326436A1 (en) 2016-09-15 2019-04-11 Prilenia Neurotherapeutics Ltd Use of pridopidine for the treatment of anxiety and depression
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia
ES2909557T3 (es) 2016-09-16 2022-05-09 Prilenia Neurotherapeutics Ltd Utilización de la pridopidina para el tratamiento del síndrome de Rett
CA3050700C (en) 2017-01-20 2023-10-03 Prilenia Neurotherapeutics Ltd. Use of pridopidine for the treatment of fragile x syndrome
HRP20251431T1 (hr) 2017-08-14 2026-01-02 Prilenia Neurotherapeutics Ltd. Liječenje amiotrofične lateralne skleroze pridopidinom
EP3675830A1 (en) 2017-08-30 2020-07-08 Prilenia Neurotherapeutics Ltd. High concentration dosage forms of pridopidine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060287299A1 (en) * 2003-12-02 2006-12-21 Sheldon Leslie J Combination therapy for dementia, depression and apathy
US20100167286A1 (en) * 2008-06-24 2010-07-01 Parkinson's Institute Pluripotent cell lines and methods of use thereof
US20140378508A1 (en) * 2013-06-21 2014-12-25 IVAX International GmbH Use of high dose pridopidine for treating huntington's disease

Also Published As

Publication number Publication date
EP4516356A3 (en) 2025-05-14
AU2017315783B2 (en) 2020-05-28
EP3504187A4 (en) 2020-05-06
CN109923102B (zh) 2022-11-15
EP3504187A1 (en) 2019-07-03
CN115671103A (zh) 2023-02-03
WO2018039477A1 (en) 2018-03-01
CL2019000485A1 (es) 2019-07-12
PT3504187T (pt) 2025-05-09
JP2019524898A (ja) 2019-09-05
EP4516356A2 (en) 2025-03-05
IL311081A (en) 2024-04-01
US11207310B2 (en) 2021-12-28
AU2017315783A1 (en) 2019-04-11
MX2019002265A (es) 2019-10-30
AU2020223736A1 (en) 2020-09-17
CA3151507A1 (en) 2018-03-01
ES3025836T3 (en) 2025-06-09
CN109923102A (zh) 2019-06-21
JP6912574B2 (ja) 2021-08-04
HUE071008T2 (hu) 2025-07-28
EP3504187B1 (en) 2025-02-19
DK3504187T3 (da) 2025-04-14
US20180055832A1 (en) 2018-03-01
CL2019003924A1 (es) 2020-05-29
BR112019003732A2 (pt) 2020-02-18
CA3151507C (en) 2024-05-28
PL3504187T3 (pl) 2025-06-09
EP3504187B8 (en) 2025-03-26
CA3035092A1 (en) 2018-03-01
NZ751156A (en) 2021-01-29
JP2021119186A (ja) 2021-08-12
AU2020223736B2 (en) 2022-04-07
MX2022003072A (es) 2022-06-17
CA3035092C (en) 2022-05-31
MX390627B (es) 2025-03-21
FI3504187T3 (fi) 2025-04-05

Similar Documents

Publication Publication Date Title
AU2020223736B2 (en) Use of pridopidine for treating a subject with early stage huntington disease
US12564582B2 (en) Use of pridopidine for treating dystonias
US12390456B2 (en) Pridopidine for treating Huntington's disease
US20230181548A1 (en) Use of pridopidine for treating functional decline
HK40115915A (en) Use of pridopidine for treating functional decline
NZ751156B2 (en) Use of pridopidine for treating functional decline
NZ791717A (en) Use of pridopidine for treating functional decline
HK40009736A (en) Use of pridopidine for treating functional decline
HK40009736B (en) Use of pridopidine for treating functional decline
US20250319076A1 (en) Use of pridopidine and analogs for treating symptoms of huntington disease
US20230355595A1 (en) Use of pridopidine for treating functional decline
EA041256B1 (ru) Применение придопидина для лечения ухудшения функциональной способности

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: PRILENIA NEUROTHERAPEUTICS LTD

Free format text: FORMER NAME(S): PRILENIA THERAPEUTICS DEVELOPMENT LTD.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ USE OF PRIDOPIDINE FOR TREATING A SUBJECT WITH EARLY STAGE HUNTINGTON DISEASE

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 27 AUG 2020

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 27 AUG 2020

FGA Letters patent sealed or granted (standard patent)